- Home
- CHRS vs HNW Comparison
CHRS vs HNW Comparison
Compare CHRS & HNW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- HNW
- Stock Information
- Founded
- CHRS 2010
- HNW 2007
- Country
- CHRS United States
- HNW United States
- Employees
- CHRS N/A
- HNW N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- HNW Finance/Investors Services
- Sector
- CHRS Health Care
- HNW Finance
- Exchange
- CHRS Nasdaq
- HNW Nasdaq
- Market Cap
- CHRS 102.0M
- HNW 104.7M
- IPO Year
- CHRS 2014
- HNW N/A
- Fundamental
- Price
- CHRS $1.05
- HNW $12.70
- Analyst Decision
- CHRS Buy
- HNW
- Analyst Count
- CHRS 3
- HNW 0
- Target Price
- CHRS $4.68
- HNW N/A
- AVG Volume (30 Days)
- CHRS 1.5M
- HNW 25.7K
- Earning Date
- CHRS 08-07-2025
- HNW 01-01-0001
- Dividend Yield
- CHRS N/A
- HNW 9.21%
- EPS Growth
- CHRS N/A
- HNW N/A
- EPS
- CHRS 1.55
- HNW 1.19
- Revenue
- CHRS $272,209,000.00
- HNW N/A
- Revenue This Year
- CHRS N/A
- HNW N/A
- Revenue Next Year
- CHRS $142.61
- HNW N/A
- P/E Ratio
- CHRS $2.05
- HNW $9.85
- Revenue Growth
- CHRS 52.33
- HNW N/A
- 52 Week Low
- CHRS $0.66
- HNW $9.80
- 52 Week High
- CHRS $2.43
- HNW $11.76
- Technical
- Relative Strength Index (RSI)
- CHRS 62.88
- HNW 77.82
- Support Level
- CHRS $0.81
- HNW $12.46
- Resistance Level
- CHRS $0.95
- HNW $12.54
- Average True Range (ATR)
- CHRS 0.07
- HNW 0.04
- MACD
- CHRS 0.01
- HNW 0.03
- Stochastic Oscillator
- CHRS 85.71
- HNW 94.87
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About HNW Pioneer Diversified High Income Fund Inc.
Pioneer Diversified High Income Trust is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income as well as capital appreciation. The company invests in various sectors such as Health Care Technology, Household Durables, Oil, Gas and Consumable Fuels, Specialty Retail, Banks, Chemicals, Financial Services, and others. It also invests in convertible bonds, common stock, asset-backed securities, and the U.S Treasury.